Pharmacological implications of MMP-9 inhibition by ACE inhibitors.
Matrix metalloproteinase-9 (MMP-9) plays an important role in the onset and prognosis of myocardial infarction. Targets of angiotensin converting enzyme (ACE) inhibitors might include not only ACE but also MMP-9, and ACE seems to be closely associated with complications of hypertension such as cardiovascular remodeling whereas MMP-9 is closely related to coronary diseases. We postulate that ACE inhibitors prevent coronary diseases via direct MMP-9 inhibition and could interact with the MMP-9 active sites using specific modes similar to those used for the ACE active sites. Research of the molecular interaction between MMP-9 active sites and ACE inhibitors appears to be an important key in the development of effective MMP-9 inhibitors for cardiovascular protection.
Biomedical Computation Center, Osaka Medical College, 2-7 Daigakuchou, Takatuski, Osaka 569-8686, Japan. center@art.osaka-med.ac.jp
Daisuke
D
Yamamoto
Shinji
S
Takai
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D050197:Atherosclerosis / Q000201:enzymology; D020134:Catalytic Domain; D005786:Gene Expression Regulation; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D009203:Myocardial Infarction / Q000188:drug therapy / Q000201:enzymology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D007703:Peptidyl-Dipeptidase A; D020780:Matrix Metalloproteinase 9